We also examined the likelihood of response to ICI therapy stratified by MUC16 mutational status and found that MUC16 mutation was enriched in patients with CR or PR for both the NSCLC cohort (10 of 20 patients with MUC16 mutation [50%] vs 7 of 36 patients with wild-type tumor [19%]; odds ratio, 4.03; 95% CI, 1.06-16.43; P = .03, Fisher exact test) and melanoma cohort (28 of 104 patients with MUC16 mutation [27%] vs 4 of 41 patients with wild-type tumor [10%]; odds ratio, 3.38; 95% CI, 1.07-14.25; P = .03, Fisher exact test) (Figure 5A and 5B). Here, MUC16 is linked to melanoma.